Global Targeted SSTR Radionuclide Drug Conjugates Market Growth (Status and Outlook) 2026-2032
The global Targeted SSTR Radionuclide Drug Conjugates market size is predicted to grow from US$ 798 million in 2025 to US$ 1291 million in 2032; it is expected to grow at a CAGR of 7.1% from 2026 to 2032.
Targeted SSTR Radionuclide Drug Conjugates are precision radiotherapeutics designed to deliver therapeutic radioisotopes to tumor tissue by targeting somatostatin receptors, or SSTR. These products are typically composed of an SSTR-targeting peptide or ligand, a chelator, and a therapeutic radionuclide, with 177Lu-labeled agents currently representing the most mature commercialized and clinically applied products. This category is mainly used for the treatment of SSTR-positive gastroenteropancreatic neuroendocrine tumors and related indications. Upstream segments mainly include targeting peptides and precursors, chelators, radioisotope production and purification, sterile radiopharmaceutical filling, and specialized cold-chain logistics, while downstream customers mainly consist of general hospitals with nuclear medicine capabilities, oncology specialty centers, and related radiopharmaceutical distribution systems. On a commercial-market basis, the global Targeted SSTR Radionuclide Drug Conjugates market in 2025 remained concentrated in a limited number of marketed products, and the industry as a whole continued to show the characteristics of limited commercialization, ongoing clinical expansion, and simultaneous manufacturing and supply-chain barriers. Because these products combine the economics of innovative oncology drugs with the operational barriers of radiopharmaceutical manufacturing, including isotope supply, dedicated facilities, quality-release requirements, and specialized distribution, gross margin is generally higher than that of conventional small-molecule drugs and standard injectables. In 2025, the gross margin of commercialized Targeted SSTR Radionuclide Drug Conjugates is estimated to be in the range of 55%-70%.
At present, the Targeted SSTR Radionuclide Drug Conjugates industry has entered a development stage driven by a limited number of commercialized products while continuing to expand into broader clinical applications. As the clinical value of radioligand therapy in neuroendocrine tumors becomes increasingly validated, targeted SSTR therapy is evolving from a relatively niche specialty treatment into an important segment within radiopharmaceutical oncology. Overall, this field combines the attributes of precision therapy and radiopharmaceutical platform technology. Market attention continues to rise, and the strategic focus of companies is gradually shifting from single-product development toward indication expansion, manufacturing capacity buildout, and global supply network improvement. The market is therefore moving from an early validation phase toward a more stable commercialization stage.
From the perspective of technology and product evolution, the 177Lu route is expected to remain the mainstream direction in the medium term, mainly because it has a stronger clinical foundation, a more established treatment pathway, and a more complete industrial support system. Future development is likely to continue deepening around core indications such as SSTR-positive gastroenteropancreatic neuroendocrine tumors, while also expanding into additional neuroendocrine tumor subtypes, combination treatment strategies, and more refined patient-selection pathways. At the same time, research on novel ligand structures, optimized dosing approaches, and improved theranostic integration is expected to continue. As a result, competition in this market will gradually shift from individual product competition to broader competition in platform capability, clinical resources, and industry-chain coordination.
From an industrialization perspective, the commercialization of Targeted SSTR Radionuclide Drug Conjugates does not depend solely on the drug product itself. It is highly dependent on radioisotope supply, dedicated manufacturing facilities, quality-release systems, cold-chain and time-sensitive distribution capabilities, and the maturity of nuclear medicine infrastructure at the treatment-center level. Compared with conventional oncology drugs, these products place much higher demands on manufacturing and distribution systems. Therefore, leading companies usually advance capacity expansion, regionalized production networks, and treatment-center coverage in parallel. In the future, companies that establish more stable isotope access, more robust manufacturing systems, and broader hospital networks at an earlier stage will be better positioned during industry expansion. This also means that entry barriers and competitive barriers in this field are likely to remain relatively high.
Nevertheless, the industry still faces multiple constraints. First, stable isotope supply, the construction cycle of dedicated production capacity, and limited nuclear medicine treatment resources remain important factors restricting further market expansion. Second, patient treatment usually depends on imaging diagnosis, pathological classification, and coordination among specialty centers, while reimbursement systems, hospital access, physician experience, and treatment standards differ across countries and regions, leading to uneven global market development. In addition, as the industry expands toward broader patient populations and more complex treatment regimens, the importance of safety management, long-term follow-up, and standardized treatment pathways will continue to increase. Overall, the Targeted SSTR Radionuclide Drug Conjugates market has clear medium- to long-term growth potential, but its expansion is more likely to take the form of steady growth supported by clinical evidence, supply-chain assurance, and healthcare-system development, rather than rapid short-term scaling.
LPI (LP Information)' newest research report, the ?Targeted SSTR Radionuclide Drug Conjugates Industry Forecast? looks at past sales and reviews total world Targeted SSTR Radionuclide Drug Conjugates sales in 2025, providing a comprehensive analysis by region and market sector of projected Targeted SSTR Radionuclide Drug Conjugates sales for 2026 through 2032. With Targeted SSTR Radionuclide Drug Conjugates sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Targeted SSTR Radionuclide Drug Conjugates industry.
This Insight Report provides a comprehensive analysis of the global Targeted SSTR Radionuclide Drug Conjugates landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Targeted SSTR Radionuclide Drug Conjugates portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms? unique position in an accelerating global Targeted SSTR Radionuclide Drug Conjugates market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Targeted SSTR Radionuclide Drug Conjugates and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Targeted SSTR Radionuclide Drug Conjugates.
This report presents a comprehensive overview, market shares, and growth opportunities of Targeted SSTR Radionuclide Drug Conjugates market by product type, application, key players and key regions and countries.
Segmentation by Type:
Targeted SSTR Radionuclide Drug Conjugates are precision radiotherapeutics designed to deliver therapeutic radioisotopes to tumor tissue by targeting somatostatin receptors, or SSTR. These products are typically composed of an SSTR-targeting peptide or ligand, a chelator, and a therapeutic radionuclide, with 177Lu-labeled agents currently representing the most mature commercialized and clinically applied products. This category is mainly used for the treatment of SSTR-positive gastroenteropancreatic neuroendocrine tumors and related indications. Upstream segments mainly include targeting peptides and precursors, chelators, radioisotope production and purification, sterile radiopharmaceutical filling, and specialized cold-chain logistics, while downstream customers mainly consist of general hospitals with nuclear medicine capabilities, oncology specialty centers, and related radiopharmaceutical distribution systems. On a commercial-market basis, the global Targeted SSTR Radionuclide Drug Conjugates market in 2025 remained concentrated in a limited number of marketed products, and the industry as a whole continued to show the characteristics of limited commercialization, ongoing clinical expansion, and simultaneous manufacturing and supply-chain barriers. Because these products combine the economics of innovative oncology drugs with the operational barriers of radiopharmaceutical manufacturing, including isotope supply, dedicated facilities, quality-release requirements, and specialized distribution, gross margin is generally higher than that of conventional small-molecule drugs and standard injectables. In 2025, the gross margin of commercialized Targeted SSTR Radionuclide Drug Conjugates is estimated to be in the range of 55%-70%.
At present, the Targeted SSTR Radionuclide Drug Conjugates industry has entered a development stage driven by a limited number of commercialized products while continuing to expand into broader clinical applications. As the clinical value of radioligand therapy in neuroendocrine tumors becomes increasingly validated, targeted SSTR therapy is evolving from a relatively niche specialty treatment into an important segment within radiopharmaceutical oncology. Overall, this field combines the attributes of precision therapy and radiopharmaceutical platform technology. Market attention continues to rise, and the strategic focus of companies is gradually shifting from single-product development toward indication expansion, manufacturing capacity buildout, and global supply network improvement. The market is therefore moving from an early validation phase toward a more stable commercialization stage.
From the perspective of technology and product evolution, the 177Lu route is expected to remain the mainstream direction in the medium term, mainly because it has a stronger clinical foundation, a more established treatment pathway, and a more complete industrial support system. Future development is likely to continue deepening around core indications such as SSTR-positive gastroenteropancreatic neuroendocrine tumors, while also expanding into additional neuroendocrine tumor subtypes, combination treatment strategies, and more refined patient-selection pathways. At the same time, research on novel ligand structures, optimized dosing approaches, and improved theranostic integration is expected to continue. As a result, competition in this market will gradually shift from individual product competition to broader competition in platform capability, clinical resources, and industry-chain coordination.
From an industrialization perspective, the commercialization of Targeted SSTR Radionuclide Drug Conjugates does not depend solely on the drug product itself. It is highly dependent on radioisotope supply, dedicated manufacturing facilities, quality-release systems, cold-chain and time-sensitive distribution capabilities, and the maturity of nuclear medicine infrastructure at the treatment-center level. Compared with conventional oncology drugs, these products place much higher demands on manufacturing and distribution systems. Therefore, leading companies usually advance capacity expansion, regionalized production networks, and treatment-center coverage in parallel. In the future, companies that establish more stable isotope access, more robust manufacturing systems, and broader hospital networks at an earlier stage will be better positioned during industry expansion. This also means that entry barriers and competitive barriers in this field are likely to remain relatively high.
Nevertheless, the industry still faces multiple constraints. First, stable isotope supply, the construction cycle of dedicated production capacity, and limited nuclear medicine treatment resources remain important factors restricting further market expansion. Second, patient treatment usually depends on imaging diagnosis, pathological classification, and coordination among specialty centers, while reimbursement systems, hospital access, physician experience, and treatment standards differ across countries and regions, leading to uneven global market development. In addition, as the industry expands toward broader patient populations and more complex treatment regimens, the importance of safety management, long-term follow-up, and standardized treatment pathways will continue to increase. Overall, the Targeted SSTR Radionuclide Drug Conjugates market has clear medium- to long-term growth potential, but its expansion is more likely to take the form of steady growth supported by clinical evidence, supply-chain assurance, and healthcare-system development, rather than rapid short-term scaling.
LPI (LP Information)' newest research report, the ?Targeted SSTR Radionuclide Drug Conjugates Industry Forecast? looks at past sales and reviews total world Targeted SSTR Radionuclide Drug Conjugates sales in 2025, providing a comprehensive analysis by region and market sector of projected Targeted SSTR Radionuclide Drug Conjugates sales for 2026 through 2032. With Targeted SSTR Radionuclide Drug Conjugates sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Targeted SSTR Radionuclide Drug Conjugates industry.
This Insight Report provides a comprehensive analysis of the global Targeted SSTR Radionuclide Drug Conjugates landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Targeted SSTR Radionuclide Drug Conjugates portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms? unique position in an accelerating global Targeted SSTR Radionuclide Drug Conjugates market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Targeted SSTR Radionuclide Drug Conjugates and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Targeted SSTR Radionuclide Drug Conjugates.
This report presents a comprehensive overview, market shares, and growth opportunities of Targeted SSTR Radionuclide Drug Conjugates market by product type, application, key players and key regions and countries.
Segmentation by Type:
- Monotherapy Products
- Combination Therapy Products
- Beta-emitting
- Alpha-emitting
- Other
- Small-molecule
- Antibody-based
- Other
- Hospital
- Specialist Clinic
- Other
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Novartis
- ITM Isotope Technologies Munich SE
- Orano Med
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Targeted SSTR Radionuclide Drug Conjugates Market Size (2021-2032)
2.1.2 Targeted SSTR Radionuclide Drug Conjugates Market Size CAGR by Region (2021 VS 2025 VS 2032)
2.1.3 World Current & Future Analysis for Targeted SSTR Radionuclide Drug Conjugates by Country/Region (2021, 2025 & 2032)
2.2 Targeted SSTR Radionuclide Drug Conjugates Segment by Type
2.2.1 Monotherapy Products
2.2.2 Combination Therapy Products
2.2.3 Targeted SSTR Radionuclide Drug Conjugates Market Size by Type
2.2.3.1 Targeted SSTR Radionuclide Drug Conjugates Market Size CAGR by Type (2021 VS 2025 VS 2032)
2.2.3.2 Global Targeted SSTR Radionuclide Drug Conjugates Market Size Market Share by Type (2021-2026)
2.3 Targeted SSTR Radionuclide Drug Conjugates Segment by Radionuclide Type
2.3.1 Beta-emitting
2.3.2 Alpha-emitting
2.3.3 Other
2.3.4 Targeted SSTR Radionuclide Drug Conjugates Market Size by Radionuclide Type
2.3.4.1 Targeted SSTR Radionuclide Drug Conjugates Market Size CAGR by Radionuclide Type (2021 VS 2025 VS 2032)
2.3.4.2 Global Targeted SSTR Radionuclide Drug Conjugates Market Size Market Share by Radionuclide Type (2021-2026)
2.4 Targeted SSTR Radionuclide Drug Conjugates Segment by Targeting Vector Type
2.4.1 Small-molecule
2.4.2 Antibody-based
2.4.3 Other
2.4.4 Targeted SSTR Radionuclide Drug Conjugates Market Size by Targeting Vector Type
2.4.4.1 Targeted SSTR Radionuclide Drug Conjugates Market Size CAGR by Targeting Vector Type (2021 VS 2025 VS 2032)
2.4.4.2 Global Targeted SSTR Radionuclide Drug Conjugates Market Size Market Share by Targeting Vector Type (2021-2026)
2.5 Targeted SSTR Radionuclide Drug Conjugates Segment by Application
2.5.1 Hospital
2.5.2 Specialist Clinic
2.5.3 Other
2.5.4 Targeted SSTR Radionuclide Drug Conjugates Market Size by Application
2.5.4.1 Targeted SSTR Radionuclide Drug Conjugates Market Size CAGR by Application (2021 VS 2025 VS 2032)
2.5.4.2 Global Targeted SSTR Radionuclide Drug Conjugates Market Size Market Share by Application (2021-2026)
3 TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE BY PLAYER
3.1 Targeted SSTR Radionuclide Drug Conjugates Market Size Market Share by Player
3.1.1 Global Targeted SSTR Radionuclide Drug Conjugates Revenue by Player (2021-2026)
3.1.2 Global Targeted SSTR Radionuclide Drug Conjugates Revenue Market Share by Player (2021-2026)
3.2 Global Targeted SSTR Radionuclide Drug Conjugates Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES BY REGION
4.1 Targeted SSTR Radionuclide Drug Conjugates Market Size by Region (2021-2026)
4.2 Global Targeted SSTR Radionuclide Drug Conjugates Annual Revenue by Country/Region (2021-2026)
4.3 Americas Targeted SSTR Radionuclide Drug Conjugates Market Size Growth (2021-2026)
4.4 APAC Targeted SSTR Radionuclide Drug Conjugates Market Size Growth (2021-2026)
4.5 Europe Targeted SSTR Radionuclide Drug Conjugates Market Size Growth (2021-2026)
4.6 Middle East & Africa Targeted SSTR Radionuclide Drug Conjugates Market Size Growth (2021-2026)
5 AMERICAS
5.1 Americas Targeted SSTR Radionuclide Drug Conjugates Market Size by Country (2021-2026)
5.2 Americas Targeted SSTR Radionuclide Drug Conjugates Market Size by Type (2021-2026)
5.3 Americas Targeted SSTR Radionuclide Drug Conjugates Market Size by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Targeted SSTR Radionuclide Drug Conjugates Market Size by Region (2021-2026)
6.2 APAC Targeted SSTR Radionuclide Drug Conjugates Market Size by Type (2021-2026)
6.3 APAC Targeted SSTR Radionuclide Drug Conjugates Market Size by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 EUROPE
7.1 Europe Targeted SSTR Radionuclide Drug Conjugates Market Size by Country (2021-2026)
7.2 Europe Targeted SSTR Radionuclide Drug Conjugates Market Size by Type (2021-2026)
7.3 Europe Targeted SSTR Radionuclide Drug Conjugates Market Size by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Targeted SSTR Radionuclide Drug Conjugates by Region (2021-2026)
8.2 Middle East & Africa Targeted SSTR Radionuclide Drug Conjugates Market Size by Type (2021-2026)
8.3 Middle East & Africa Targeted SSTR Radionuclide Drug Conjugates Market Size by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 GLOBAL TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET FORECAST
10.1 Global Targeted SSTR Radionuclide Drug Conjugates Forecast by Region (2027-2032)
10.1.1 Global Targeted SSTR Radionuclide Drug Conjugates Forecast by Region (2027-2032)
10.1.2 Americas Targeted SSTR Radionuclide Drug Conjugates Forecast
10.1.3 APAC Targeted SSTR Radionuclide Drug Conjugates Forecast
10.1.4 Europe Targeted SSTR Radionuclide Drug Conjugates Forecast
10.1.5 Middle East & Africa Targeted SSTR Radionuclide Drug Conjugates Forecast
10.2 Americas Targeted SSTR Radionuclide Drug Conjugates Forecast by Country (2027-2032)
10.2.1 United States Market Targeted SSTR Radionuclide Drug Conjugates Forecast
10.2.2 Canada Market Targeted SSTR Radionuclide Drug Conjugates Forecast
10.2.3 Mexico Market Targeted SSTR Radionuclide Drug Conjugates Forecast
10.2.4 Brazil Market Targeted SSTR Radionuclide Drug Conjugates Forecast
10.3 APAC Targeted SSTR Radionuclide Drug Conjugates Forecast by Region (2027-2032)
10.3.1 China Targeted SSTR Radionuclide Drug Conjugates Market Forecast
10.3.2 Japan Market Targeted SSTR Radionuclide Drug Conjugates Forecast
10.3.3 Korea Market Targeted SSTR Radionuclide Drug Conjugates Forecast
10.3.4 Southeast Asia Market Targeted SSTR Radionuclide Drug Conjugates Forecast
10.3.5 India Market Targeted SSTR Radionuclide Drug Conjugates Forecast
10.3.6 Australia Market Targeted SSTR Radionuclide Drug Conjugates Forecast
10.4 Europe Targeted SSTR Radionuclide Drug Conjugates Forecast by Country (2027-2032)
10.4.1 Germany Market Targeted SSTR Radionuclide Drug Conjugates Forecast
10.4.2 France Market Targeted SSTR Radionuclide Drug Conjugates Forecast
10.4.3 UK Market Targeted SSTR Radionuclide Drug Conjugates Forecast
10.4.4 Italy Market Targeted SSTR Radionuclide Drug Conjugates Forecast
10.4.5 Russia Market Targeted SSTR Radionuclide Drug Conjugates Forecast
10.5 Middle East & Africa Targeted SSTR Radionuclide Drug Conjugates Forecast by Region (2027-2032)
10.5.1 Egypt Market Targeted SSTR Radionuclide Drug Conjugates Forecast
10.5.2 South Africa Market Targeted SSTR Radionuclide Drug Conjugates Forecast
10.5.3 Israel Market Targeted SSTR Radionuclide Drug Conjugates Forecast
10.5.4 Turkey Market Targeted SSTR Radionuclide Drug Conjugates Forecast
10.6 Global Targeted SSTR Radionuclide Drug Conjugates Forecast by Type (2027-2032)
10.7 Global Targeted SSTR Radionuclide Drug Conjugates Forecast by Application (2027-2032)
10.7.1 GCC Countries Market Targeted SSTR Radionuclide Drug Conjugates Forecast
11 KEY PLAYERS ANALYSIS
11.1 Novartis
11.1.1 Novartis Company Information
11.1.2 Novartis Targeted SSTR Radionuclide Drug Conjugates Product Offered
11.1.3 Novartis Targeted SSTR Radionuclide Drug Conjugates Revenue, Gross Margin and Market Share (2021-2026)
11.1.4 Novartis Main Business Overview
11.1.5 Novartis Latest Developments
11.2 ITM Isotope Technologies Munich SE
11.2.1 ITM Isotope Technologies Munich SE Company Information
11.2.2 ITM Isotope Technologies Munich SE Targeted SSTR Radionuclide Drug Conjugates Product Offered
11.2.3 ITM Isotope Technologies Munich SE Targeted SSTR Radionuclide Drug Conjugates Revenue, Gross Margin and Market Share (2021-2026)
11.2.4 ITM Isotope Technologies Munich SE Main Business Overview
11.2.5 ITM Isotope Technologies Munich SE Latest Developments
11.3 Orano Med
11.3.1 Orano Med Company Information
11.3.2 Orano Med Targeted SSTR Radionuclide Drug Conjugates Product Offered
11.3.3 Orano Med Targeted SSTR Radionuclide Drug Conjugates Revenue, Gross Margin and Market Share (2021-2026)
11.3.4 Orano Med Main Business Overview
11.3.5 Orano Med Latest Developments
12 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Targeted SSTR Radionuclide Drug Conjugates Market Size (2021-2032)
2.1.2 Targeted SSTR Radionuclide Drug Conjugates Market Size CAGR by Region (2021 VS 2025 VS 2032)
2.1.3 World Current & Future Analysis for Targeted SSTR Radionuclide Drug Conjugates by Country/Region (2021, 2025 & 2032)
2.2 Targeted SSTR Radionuclide Drug Conjugates Segment by Type
2.2.1 Monotherapy Products
2.2.2 Combination Therapy Products
2.2.3 Targeted SSTR Radionuclide Drug Conjugates Market Size by Type
2.2.3.1 Targeted SSTR Radionuclide Drug Conjugates Market Size CAGR by Type (2021 VS 2025 VS 2032)
2.2.3.2 Global Targeted SSTR Radionuclide Drug Conjugates Market Size Market Share by Type (2021-2026)
2.3 Targeted SSTR Radionuclide Drug Conjugates Segment by Radionuclide Type
2.3.1 Beta-emitting
2.3.2 Alpha-emitting
2.3.3 Other
2.3.4 Targeted SSTR Radionuclide Drug Conjugates Market Size by Radionuclide Type
2.3.4.1 Targeted SSTR Radionuclide Drug Conjugates Market Size CAGR by Radionuclide Type (2021 VS 2025 VS 2032)
2.3.4.2 Global Targeted SSTR Radionuclide Drug Conjugates Market Size Market Share by Radionuclide Type (2021-2026)
2.4 Targeted SSTR Radionuclide Drug Conjugates Segment by Targeting Vector Type
2.4.1 Small-molecule
2.4.2 Antibody-based
2.4.3 Other
2.4.4 Targeted SSTR Radionuclide Drug Conjugates Market Size by Targeting Vector Type
2.4.4.1 Targeted SSTR Radionuclide Drug Conjugates Market Size CAGR by Targeting Vector Type (2021 VS 2025 VS 2032)
2.4.4.2 Global Targeted SSTR Radionuclide Drug Conjugates Market Size Market Share by Targeting Vector Type (2021-2026)
2.5 Targeted SSTR Radionuclide Drug Conjugates Segment by Application
2.5.1 Hospital
2.5.2 Specialist Clinic
2.5.3 Other
2.5.4 Targeted SSTR Radionuclide Drug Conjugates Market Size by Application
2.5.4.1 Targeted SSTR Radionuclide Drug Conjugates Market Size CAGR by Application (2021 VS 2025 VS 2032)
2.5.4.2 Global Targeted SSTR Radionuclide Drug Conjugates Market Size Market Share by Application (2021-2026)
3 TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE BY PLAYER
3.1 Targeted SSTR Radionuclide Drug Conjugates Market Size Market Share by Player
3.1.1 Global Targeted SSTR Radionuclide Drug Conjugates Revenue by Player (2021-2026)
3.1.2 Global Targeted SSTR Radionuclide Drug Conjugates Revenue Market Share by Player (2021-2026)
3.2 Global Targeted SSTR Radionuclide Drug Conjugates Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES BY REGION
4.1 Targeted SSTR Radionuclide Drug Conjugates Market Size by Region (2021-2026)
4.2 Global Targeted SSTR Radionuclide Drug Conjugates Annual Revenue by Country/Region (2021-2026)
4.3 Americas Targeted SSTR Radionuclide Drug Conjugates Market Size Growth (2021-2026)
4.4 APAC Targeted SSTR Radionuclide Drug Conjugates Market Size Growth (2021-2026)
4.5 Europe Targeted SSTR Radionuclide Drug Conjugates Market Size Growth (2021-2026)
4.6 Middle East & Africa Targeted SSTR Radionuclide Drug Conjugates Market Size Growth (2021-2026)
5 AMERICAS
5.1 Americas Targeted SSTR Radionuclide Drug Conjugates Market Size by Country (2021-2026)
5.2 Americas Targeted SSTR Radionuclide Drug Conjugates Market Size by Type (2021-2026)
5.3 Americas Targeted SSTR Radionuclide Drug Conjugates Market Size by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Targeted SSTR Radionuclide Drug Conjugates Market Size by Region (2021-2026)
6.2 APAC Targeted SSTR Radionuclide Drug Conjugates Market Size by Type (2021-2026)
6.3 APAC Targeted SSTR Radionuclide Drug Conjugates Market Size by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 EUROPE
7.1 Europe Targeted SSTR Radionuclide Drug Conjugates Market Size by Country (2021-2026)
7.2 Europe Targeted SSTR Radionuclide Drug Conjugates Market Size by Type (2021-2026)
7.3 Europe Targeted SSTR Radionuclide Drug Conjugates Market Size by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Targeted SSTR Radionuclide Drug Conjugates by Region (2021-2026)
8.2 Middle East & Africa Targeted SSTR Radionuclide Drug Conjugates Market Size by Type (2021-2026)
8.3 Middle East & Africa Targeted SSTR Radionuclide Drug Conjugates Market Size by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 GLOBAL TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET FORECAST
10.1 Global Targeted SSTR Radionuclide Drug Conjugates Forecast by Region (2027-2032)
10.1.1 Global Targeted SSTR Radionuclide Drug Conjugates Forecast by Region (2027-2032)
10.1.2 Americas Targeted SSTR Radionuclide Drug Conjugates Forecast
10.1.3 APAC Targeted SSTR Radionuclide Drug Conjugates Forecast
10.1.4 Europe Targeted SSTR Radionuclide Drug Conjugates Forecast
10.1.5 Middle East & Africa Targeted SSTR Radionuclide Drug Conjugates Forecast
10.2 Americas Targeted SSTR Radionuclide Drug Conjugates Forecast by Country (2027-2032)
10.2.1 United States Market Targeted SSTR Radionuclide Drug Conjugates Forecast
10.2.2 Canada Market Targeted SSTR Radionuclide Drug Conjugates Forecast
10.2.3 Mexico Market Targeted SSTR Radionuclide Drug Conjugates Forecast
10.2.4 Brazil Market Targeted SSTR Radionuclide Drug Conjugates Forecast
10.3 APAC Targeted SSTR Radionuclide Drug Conjugates Forecast by Region (2027-2032)
10.3.1 China Targeted SSTR Radionuclide Drug Conjugates Market Forecast
10.3.2 Japan Market Targeted SSTR Radionuclide Drug Conjugates Forecast
10.3.3 Korea Market Targeted SSTR Radionuclide Drug Conjugates Forecast
10.3.4 Southeast Asia Market Targeted SSTR Radionuclide Drug Conjugates Forecast
10.3.5 India Market Targeted SSTR Radionuclide Drug Conjugates Forecast
10.3.6 Australia Market Targeted SSTR Radionuclide Drug Conjugates Forecast
10.4 Europe Targeted SSTR Radionuclide Drug Conjugates Forecast by Country (2027-2032)
10.4.1 Germany Market Targeted SSTR Radionuclide Drug Conjugates Forecast
10.4.2 France Market Targeted SSTR Radionuclide Drug Conjugates Forecast
10.4.3 UK Market Targeted SSTR Radionuclide Drug Conjugates Forecast
10.4.4 Italy Market Targeted SSTR Radionuclide Drug Conjugates Forecast
10.4.5 Russia Market Targeted SSTR Radionuclide Drug Conjugates Forecast
10.5 Middle East & Africa Targeted SSTR Radionuclide Drug Conjugates Forecast by Region (2027-2032)
10.5.1 Egypt Market Targeted SSTR Radionuclide Drug Conjugates Forecast
10.5.2 South Africa Market Targeted SSTR Radionuclide Drug Conjugates Forecast
10.5.3 Israel Market Targeted SSTR Radionuclide Drug Conjugates Forecast
10.5.4 Turkey Market Targeted SSTR Radionuclide Drug Conjugates Forecast
10.6 Global Targeted SSTR Radionuclide Drug Conjugates Forecast by Type (2027-2032)
10.7 Global Targeted SSTR Radionuclide Drug Conjugates Forecast by Application (2027-2032)
10.7.1 GCC Countries Market Targeted SSTR Radionuclide Drug Conjugates Forecast
11 KEY PLAYERS ANALYSIS
11.1 Novartis
11.1.1 Novartis Company Information
11.1.2 Novartis Targeted SSTR Radionuclide Drug Conjugates Product Offered
11.1.3 Novartis Targeted SSTR Radionuclide Drug Conjugates Revenue, Gross Margin and Market Share (2021-2026)
11.1.4 Novartis Main Business Overview
11.1.5 Novartis Latest Developments
11.2 ITM Isotope Technologies Munich SE
11.2.1 ITM Isotope Technologies Munich SE Company Information
11.2.2 ITM Isotope Technologies Munich SE Targeted SSTR Radionuclide Drug Conjugates Product Offered
11.2.3 ITM Isotope Technologies Munich SE Targeted SSTR Radionuclide Drug Conjugates Revenue, Gross Margin and Market Share (2021-2026)
11.2.4 ITM Isotope Technologies Munich SE Main Business Overview
11.2.5 ITM Isotope Technologies Munich SE Latest Developments
11.3 Orano Med
11.3.1 Orano Med Company Information
11.3.2 Orano Med Targeted SSTR Radionuclide Drug Conjugates Product Offered
11.3.3 Orano Med Targeted SSTR Radionuclide Drug Conjugates Revenue, Gross Margin and Market Share (2021-2026)
11.3.4 Orano Med Main Business Overview
11.3.5 Orano Med Latest Developments
12 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Targeted SSTR Radionuclide Drug Conjugates Market Size CAGR by Region (2021 VS 2025 VS 2032) & ($ millions)
Table 2. Targeted SSTR Radionuclide Drug Conjugates Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Monotherapy Products
Table 4. Major Players of Combination Therapy Products
Table 5. Targeted SSTR Radionuclide Drug Conjugates Market Size CAGR by Type (2021 VS 2025 VS 2032) & ($ millions)
Table 6. Global Targeted SSTR Radionuclide Drug Conjugates Market Size by Type (2021-2026) & ($ millions)
Table 7. Global Targeted SSTR Radionuclide Drug Conjugates Market Size Market Share by Type (2021-2026)
Table 8. Major Players of Beta-emitting
Table 9. Major Players of Alpha-emitting
Table 10. Major Players of Other
Table 11. Targeted SSTR Radionuclide Drug Conjugates Market Size CAGR by Radionuclide Type (2021 VS 2025 VS 2032) & ($ millions)
Table 12. Global Targeted SSTR Radionuclide Drug Conjugates Market Size by Radionuclide Type (2021-2026) & ($ millions)
Table 13. Global Targeted SSTR Radionuclide Drug Conjugates Market Size Market Share by Radionuclide Type (2021-2026)
Table 14. Major Players of Small-molecule
Table 15. Major Players of Antibody-based
Table 16. Major Players of Other
Table 17. Targeted SSTR Radionuclide Drug Conjugates Market Size CAGR by Targeting Vector Type (2021 VS 2025 VS 2032) & ($ millions)
Table 18. Global Targeted SSTR Radionuclide Drug Conjugates Market Size by Targeting Vector Type (2021-2026) & ($ millions)
Table 19. Global Targeted SSTR Radionuclide Drug Conjugates Market Size Market Share by Targeting Vector Type (2021-2026)
Table 20. Targeted SSTR Radionuclide Drug Conjugates Market Size CAGR by Application (2021 VS 2025 VS 2032) & ($ millions)
Table 21. Global Targeted SSTR Radionuclide Drug Conjugates Market Size by Application (2021-2026) & ($ millions)
Table 22. Global Targeted SSTR Radionuclide Drug Conjugates Market Size Market Share by Application (2021-2026)
Table 23. Global Targeted SSTR Radionuclide Drug Conjugates Revenue by Player (2021-2026) & ($ millions)
Table 24. Global Targeted SSTR Radionuclide Drug Conjugates Revenue Market Share by Player (2021-2026)
Table 25. Targeted SSTR Radionuclide Drug Conjugates Key Players Head office and Products Offered
Table 26. Targeted SSTR Radionuclide Drug Conjugates Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 27. New Products and Potential Entrants
Table 28. Mergers & Acquisitions, Expansion
Table 29. Global Targeted SSTR Radionuclide Drug Conjugates Market Size by Region (2021-2026) & ($ millions)
Table 30. Global Targeted SSTR Radionuclide Drug Conjugates Market Size Market Share by Region (2021-2026)
Table 31. Global Targeted SSTR Radionuclide Drug Conjugates Revenue by Country/Region (2021-2026) & ($ millions)
Table 32. Global Targeted SSTR Radionuclide Drug Conjugates Revenue Market Share by Country/Region (2021-2026)
Table 33. Americas Targeted SSTR Radionuclide Drug Conjugates Market Size by Country (2021-2026) & ($ millions)
Table 34. Americas Targeted SSTR Radionuclide Drug Conjugates Market Size Market Share by Country (2021-2026)
Table 35. Americas Targeted SSTR Radionuclide Drug Conjugates Market Size by Type (2021-2026) & ($ millions)
Table 36. Americas Targeted SSTR Radionuclide Drug Conjugates Market Size Market Share by Type (2021-2026)
Table 37. Americas Targeted SSTR Radionuclide Drug Conjugates Market Size by Application (2021-2026) & ($ millions)
Table 38. Americas Targeted SSTR Radionuclide Drug Conjugates Market Size Market Share by Application (2021-2026)
Table 39. APAC Targeted SSTR Radionuclide Drug Conjugates Market Size by Region (2021-2026) & ($ millions)
Table 40. APAC Targeted SSTR Radionuclide Drug Conjugates Market Size Market Share by Region (2021-2026)
Table 41. APAC Targeted SSTR Radionuclide Drug Conjugates Market Size by Type (2021-2026) & ($ millions)
Table 42. APAC Targeted SSTR Radionuclide Drug Conjugates Market Size by Application (2021-2026) & ($ millions)
Table 43. Europe Targeted SSTR Radionuclide Drug Conjugates Market Size by Country (2021-2026) & ($ millions)
Table 44. Europe Targeted SSTR Radionuclide Drug Conjugates Market Size Market Share by Country (2021-2026)
Table 45. Europe Targeted SSTR Radionuclide Drug Conjugates Market Size by Type (2021-2026) & ($ millions)
Table 46. Europe Targeted SSTR Radionuclide Drug Conjugates Market Size by Application (2021-2026) & ($ millions)
Table 47. Middle East & Africa Targeted SSTR Radionuclide Drug Conjugates Market Size by Region (2021-2026) & ($ millions)
Table 48. Middle East & Africa Targeted SSTR Radionuclide Drug Conjugates Market Size by Type (2021-2026) & ($ millions)
Table 49. Middle East & Africa Targeted SSTR Radionuclide Drug Conjugates Market Size by Application (2021-2026) & ($ millions)
Table 50. Key Market Drivers & Growth Opportunities of Targeted SSTR Radionuclide Drug Conjugates
Table 51. Key Market Challenges & Risks of Targeted SSTR Radionuclide Drug Conjugates
Table 52. Key Industry Trends of Targeted SSTR Radionuclide Drug Conjugates
Table 53. Global Targeted SSTR Radionuclide Drug Conjugates Market Size Forecast by Region (2027-2032) & ($ millions)
Table 54. Global Targeted SSTR Radionuclide Drug Conjugates Market Size Market Share Forecast by Region (2027-2032)
Table 55. Global Targeted SSTR Radionuclide Drug Conjugates Market Size Forecast by Type (2027-2032) & ($ millions)
Table 56. Global Targeted SSTR Radionuclide Drug Conjugates Market Size Forecast by Application (2027-2032) & ($ millions)
Table 57. Novartis Details, Company Type, Targeted SSTR Radionuclide Drug Conjugates Area Served and Its Competitors
Table 58. Novartis Targeted SSTR Radionuclide Drug Conjugates Product Offered
Table 59. Novartis Targeted SSTR Radionuclide Drug Conjugates Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 60. Novartis Main Business
Table 61. Novartis Latest Developments
Table 62. ITM Isotope Technologies Munich SE Details, Company Type, Targeted SSTR Radionuclide Drug Conjugates Area Served and Its Competitors
Table 63. ITM Isotope Technologies Munich SE Targeted SSTR Radionuclide Drug Conjugates Product Offered
Table 64. ITM Isotope Technologies Munich SE Targeted SSTR Radionuclide Drug Conjugates Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 65. ITM Isotope Technologies Munich SE Main Business
Table 66. ITM Isotope Technologies Munich SE Latest Developments
Table 67. Orano Med Details, Company Type, Targeted SSTR Radionuclide Drug Conjugates Area Served and Its Competitors
Table 68. Orano Med Targeted SSTR Radionuclide Drug Conjugates Product Offered
Table 69. Orano Med Targeted SSTR Radionuclide Drug Conjugates Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 70. Orano Med Main Business
Table 71. Orano Med Latest Developments
Table 1. Targeted SSTR Radionuclide Drug Conjugates Market Size CAGR by Region (2021 VS 2025 VS 2032) & ($ millions)
Table 2. Targeted SSTR Radionuclide Drug Conjugates Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Monotherapy Products
Table 4. Major Players of Combination Therapy Products
Table 5. Targeted SSTR Radionuclide Drug Conjugates Market Size CAGR by Type (2021 VS 2025 VS 2032) & ($ millions)
Table 6. Global Targeted SSTR Radionuclide Drug Conjugates Market Size by Type (2021-2026) & ($ millions)
Table 7. Global Targeted SSTR Radionuclide Drug Conjugates Market Size Market Share by Type (2021-2026)
Table 8. Major Players of Beta-emitting
Table 9. Major Players of Alpha-emitting
Table 10. Major Players of Other
Table 11. Targeted SSTR Radionuclide Drug Conjugates Market Size CAGR by Radionuclide Type (2021 VS 2025 VS 2032) & ($ millions)
Table 12. Global Targeted SSTR Radionuclide Drug Conjugates Market Size by Radionuclide Type (2021-2026) & ($ millions)
Table 13. Global Targeted SSTR Radionuclide Drug Conjugates Market Size Market Share by Radionuclide Type (2021-2026)
Table 14. Major Players of Small-molecule
Table 15. Major Players of Antibody-based
Table 16. Major Players of Other
Table 17. Targeted SSTR Radionuclide Drug Conjugates Market Size CAGR by Targeting Vector Type (2021 VS 2025 VS 2032) & ($ millions)
Table 18. Global Targeted SSTR Radionuclide Drug Conjugates Market Size by Targeting Vector Type (2021-2026) & ($ millions)
Table 19. Global Targeted SSTR Radionuclide Drug Conjugates Market Size Market Share by Targeting Vector Type (2021-2026)
Table 20. Targeted SSTR Radionuclide Drug Conjugates Market Size CAGR by Application (2021 VS 2025 VS 2032) & ($ millions)
Table 21. Global Targeted SSTR Radionuclide Drug Conjugates Market Size by Application (2021-2026) & ($ millions)
Table 22. Global Targeted SSTR Radionuclide Drug Conjugates Market Size Market Share by Application (2021-2026)
Table 23. Global Targeted SSTR Radionuclide Drug Conjugates Revenue by Player (2021-2026) & ($ millions)
Table 24. Global Targeted SSTR Radionuclide Drug Conjugates Revenue Market Share by Player (2021-2026)
Table 25. Targeted SSTR Radionuclide Drug Conjugates Key Players Head office and Products Offered
Table 26. Targeted SSTR Radionuclide Drug Conjugates Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 27. New Products and Potential Entrants
Table 28. Mergers & Acquisitions, Expansion
Table 29. Global Targeted SSTR Radionuclide Drug Conjugates Market Size by Region (2021-2026) & ($ millions)
Table 30. Global Targeted SSTR Radionuclide Drug Conjugates Market Size Market Share by Region (2021-2026)
Table 31. Global Targeted SSTR Radionuclide Drug Conjugates Revenue by Country/Region (2021-2026) & ($ millions)
Table 32. Global Targeted SSTR Radionuclide Drug Conjugates Revenue Market Share by Country/Region (2021-2026)
Table 33. Americas Targeted SSTR Radionuclide Drug Conjugates Market Size by Country (2021-2026) & ($ millions)
Table 34. Americas Targeted SSTR Radionuclide Drug Conjugates Market Size Market Share by Country (2021-2026)
Table 35. Americas Targeted SSTR Radionuclide Drug Conjugates Market Size by Type (2021-2026) & ($ millions)
Table 36. Americas Targeted SSTR Radionuclide Drug Conjugates Market Size Market Share by Type (2021-2026)
Table 37. Americas Targeted SSTR Radionuclide Drug Conjugates Market Size by Application (2021-2026) & ($ millions)
Table 38. Americas Targeted SSTR Radionuclide Drug Conjugates Market Size Market Share by Application (2021-2026)
Table 39. APAC Targeted SSTR Radionuclide Drug Conjugates Market Size by Region (2021-2026) & ($ millions)
Table 40. APAC Targeted SSTR Radionuclide Drug Conjugates Market Size Market Share by Region (2021-2026)
Table 41. APAC Targeted SSTR Radionuclide Drug Conjugates Market Size by Type (2021-2026) & ($ millions)
Table 42. APAC Targeted SSTR Radionuclide Drug Conjugates Market Size by Application (2021-2026) & ($ millions)
Table 43. Europe Targeted SSTR Radionuclide Drug Conjugates Market Size by Country (2021-2026) & ($ millions)
Table 44. Europe Targeted SSTR Radionuclide Drug Conjugates Market Size Market Share by Country (2021-2026)
Table 45. Europe Targeted SSTR Radionuclide Drug Conjugates Market Size by Type (2021-2026) & ($ millions)
Table 46. Europe Targeted SSTR Radionuclide Drug Conjugates Market Size by Application (2021-2026) & ($ millions)
Table 47. Middle East & Africa Targeted SSTR Radionuclide Drug Conjugates Market Size by Region (2021-2026) & ($ millions)
Table 48. Middle East & Africa Targeted SSTR Radionuclide Drug Conjugates Market Size by Type (2021-2026) & ($ millions)
Table 49. Middle East & Africa Targeted SSTR Radionuclide Drug Conjugates Market Size by Application (2021-2026) & ($ millions)
Table 50. Key Market Drivers & Growth Opportunities of Targeted SSTR Radionuclide Drug Conjugates
Table 51. Key Market Challenges & Risks of Targeted SSTR Radionuclide Drug Conjugates
Table 52. Key Industry Trends of Targeted SSTR Radionuclide Drug Conjugates
Table 53. Global Targeted SSTR Radionuclide Drug Conjugates Market Size Forecast by Region (2027-2032) & ($ millions)
Table 54. Global Targeted SSTR Radionuclide Drug Conjugates Market Size Market Share Forecast by Region (2027-2032)
Table 55. Global Targeted SSTR Radionuclide Drug Conjugates Market Size Forecast by Type (2027-2032) & ($ millions)
Table 56. Global Targeted SSTR Radionuclide Drug Conjugates Market Size Forecast by Application (2027-2032) & ($ millions)
Table 57. Novartis Details, Company Type, Targeted SSTR Radionuclide Drug Conjugates Area Served and Its Competitors
Table 58. Novartis Targeted SSTR Radionuclide Drug Conjugates Product Offered
Table 59. Novartis Targeted SSTR Radionuclide Drug Conjugates Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 60. Novartis Main Business
Table 61. Novartis Latest Developments
Table 62. ITM Isotope Technologies Munich SE Details, Company Type, Targeted SSTR Radionuclide Drug Conjugates Area Served and Its Competitors
Table 63. ITM Isotope Technologies Munich SE Targeted SSTR Radionuclide Drug Conjugates Product Offered
Table 64. ITM Isotope Technologies Munich SE Targeted SSTR Radionuclide Drug Conjugates Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 65. ITM Isotope Technologies Munich SE Main Business
Table 66. ITM Isotope Technologies Munich SE Latest Developments
Table 67. Orano Med Details, Company Type, Targeted SSTR Radionuclide Drug Conjugates Area Served and Its Competitors
Table 68. Orano Med Targeted SSTR Radionuclide Drug Conjugates Product Offered
Table 69. Orano Med Targeted SSTR Radionuclide Drug Conjugates Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 70. Orano Med Main Business
Table 71. Orano Med Latest Developments
LIST OF FIGURES
Figure 1. Targeted SSTR Radionuclide Drug Conjugates Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global Targeted SSTR Radionuclide Drug Conjugates Market Size Growth Rate (2021-2032) ($ millions)
Figure 6. Targeted SSTR Radionuclide Drug Conjugates Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 7. Targeted SSTR Radionuclide Drug Conjugates Sales Market Share by Country/Region (2025)
Figure 8. Targeted SSTR Radionuclide Drug Conjugates Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 9. Global Targeted SSTR Radionuclide Drug Conjugates Market Size Market Share by Type in 2025
Figure 10. Global Targeted SSTR Radionuclide Drug Conjugates Market Size Market Share by Radionuclide Type in 2025
Figure 11. Global Targeted SSTR Radionuclide Drug Conjugates Market Size Market Share by Targeting Vector Type in 2025
Figure 12. Targeted SSTR Radionuclide Drug Conjugates in Hospital
Figure 13. Global Targeted SSTR Radionuclide Drug Conjugates Market: Hospital (2021-2026) & ($ millions)
Figure 14. Targeted SSTR Radionuclide Drug Conjugates in Specialist Clinic
Figure 15. Global Targeted SSTR Radionuclide Drug Conjugates Market: Specialist Clinic (2021-2026) & ($ millions)
Figure 16. Targeted SSTR Radionuclide Drug Conjugates in Other
Figure 17. Global Targeted SSTR Radionuclide Drug Conjugates Market: Other (2021-2026) & ($ millions)
Figure 18. Global Targeted SSTR Radionuclide Drug Conjugates Market Size Market Share by Application in 2025
Figure 19. Global Targeted SSTR Radionuclide Drug Conjugates Revenue Market Share by Player in 2025
Figure 20. Global Targeted SSTR Radionuclide Drug Conjugates Market Size Market Share by Region (2021-2026)
Figure 21. Americas Targeted SSTR Radionuclide Drug Conjugates Market Size 2021-2026 ($ millions)
Figure 22. APAC Targeted SSTR Radionuclide Drug Conjugates Market Size 2021-2026 ($ millions)
Figure 23. Europe Targeted SSTR Radionuclide Drug Conjugates Market Size 2021-2026 ($ millions)
Figure 24. Middle East & Africa Targeted SSTR Radionuclide Drug Conjugates Market Size 2021-2026 ($ millions)
Figure 25. Americas Targeted SSTR Radionuclide Drug Conjugates Value Market Share by Country in 2025
Figure 26. United States Targeted SSTR Radionuclide Drug Conjugates Market Size Growth 2021-2026 ($ millions)
Figure 27. Canada Targeted SSTR Radionuclide Drug Conjugates Market Size Growth 2021-2026 ($ millions)
Figure 28. Mexico Targeted SSTR Radionuclide Drug Conjugates Market Size Growth 2021-2026 ($ millions)
Figure 29. Brazil Targeted SSTR Radionuclide Drug Conjugates Market Size Growth 2021-2026 ($ millions)
Figure 30. APAC Targeted SSTR Radionuclide Drug Conjugates Market Size Market Share by Region in 2025
Figure 31. APAC Targeted SSTR Radionuclide Drug Conjugates Market Size Market Share by Type (2021-2026)
Figure 32. APAC Targeted SSTR Radionuclide Drug Conjugates Market Size Market Share by Application (2021-2026)
Figure 33. China Targeted SSTR Radionuclide Drug Conjugates Market Size Growth 2021-2026 ($ millions)
Figure 34. Japan Targeted SSTR Radionuclide Drug Conjugates Market Size Growth 2021-2026 ($ millions)
Figure 35. South Korea Targeted SSTR Radionuclide Drug Conjugates Market Size Growth 2021-2026 ($ millions)
Figure 36. Southeast Asia Targeted SSTR Radionuclide Drug Conjugates Market Size Growth 2021-2026 ($ millions)
Figure 37. India Targeted SSTR Radionuclide Drug Conjugates Market Size Growth 2021-2026 ($ millions)
Figure 38. Australia Targeted SSTR Radionuclide Drug Conjugates Market Size Growth 2021-2026 ($ millions)
Figure 39. Europe Targeted SSTR Radionuclide Drug Conjugates Market Size Market Share by Country in 2025
Figure 40. Europe Targeted SSTR Radionuclide Drug Conjugates Market Size Market Share by Type (2021-2026)
Figure 41. Europe Targeted SSTR Radionuclide Drug Conjugates Market Size Market Share by Application (2021-2026)
Figure 42. Germany Targeted SSTR Radionuclide Drug Conjugates Market Size Growth 2021-2026 ($ millions)
Figure 43. France Targeted SSTR Radionuclide Drug Conjugates Market Size Growth 2021-2026 ($ millions)
Figure 44. UK Targeted SSTR Radionuclide Drug Conjugates Market Size Growth 2021-2026 ($ millions)
Figure 45. Italy Targeted SSTR Radionuclide Drug Conjugates Market Size Growth 2021-2026 ($ millions)
Figure 46. Russia Targeted SSTR Radionuclide Drug Conjugates Market Size Growth 2021-2026 ($ millions)
Figure 47. Middle East & Africa Targeted SSTR Radionuclide Drug Conjugates Market Size Market Share by Region (2021-2026)
Figure 48. Middle East & Africa Targeted SSTR Radionuclide Drug Conjugates Market Size Market Share by Type (2021-2026)
Figure 49. Middle East & Africa Targeted SSTR Radionuclide Drug Conjugates Market Size Market Share by Application (2021-2026)
Figure 50. Egypt Targeted SSTR Radionuclide Drug Conjugates Market Size Growth 2021-2026 ($ millions)
Figure 51. South Africa Targeted SSTR Radionuclide Drug Conjugates Market Size Growth 2021-2026 ($ millions)
Figure 52. Israel Targeted SSTR Radionuclide Drug Conjugates Market Size Growth 2021-2026 ($ millions)
Figure 53. Turkey Targeted SSTR Radionuclide Drug Conjugates Market Size Growth 2021-2026 ($ millions)
Figure 54. GCC Countries Targeted SSTR Radionuclide Drug Conjugates Market Size Growth 2021-2026 ($ millions)
Figure 55. Americas Targeted SSTR Radionuclide Drug Conjugates Market Size 2027-2032 ($ millions)
Figure 56. APAC Targeted SSTR Radionuclide Drug Conjugates Market Size 2027-2032 ($ millions)
Figure 57. Europe Targeted SSTR Radionuclide Drug Conjugates Market Size 2027-2032 ($ millions)
Figure 58. Middle East & Africa Targeted SSTR Radionuclide Drug Conjugates Market Size 2027-2032 ($ millions)
Figure 59. United States Targeted SSTR Radionuclide Drug Conjugates Market Size 2027-2032 ($ millions)
Figure 60. Canada Targeted SSTR Radionuclide Drug Conjugates Market Size 2027-2032 ($ millions)
Figure 61. Mexico Targeted SSTR Radionuclide Drug Conjugates Market Size 2027-2032 ($ millions)
Figure 62. Brazil Targeted SSTR Radionuclide Drug Conjugates Market Size 2027-2032 ($ millions)
Figure 63. China Targeted SSTR Radionuclide Drug Conjugates Market Size 2027-2032 ($ millions)
Figure 64. Japan Targeted SSTR Radionuclide Drug Conjugates Market Size 2027-2032 ($ millions)
Figure 65. Korea Targeted SSTR Radionuclide Drug Conjugates Market Size 2027-2032 ($ millions)
Figure 66. Southeast Asia Targeted SSTR Radionuclide Drug Conjugates Market Size 2027-2032 ($ millions)
Figure 67. India Targeted SSTR Radionuclide Drug Conjugates Market Size 2027-2032 ($ millions)
Figure 68. Australia Targeted SSTR Radionuclide Drug Conjugates Market Size 2027-2032 ($ millions)
Figure 69. Germany Targeted SSTR Radionuclide Drug Conjugates Market Size 2027-2032 ($ millions)
Figure 70. France Targeted SSTR Radionuclide Drug Conjugates Market Size 2027-2032 ($ millions)
Figure 71. UK Targeted SSTR Radionuclide Drug Conjugates Market Size 2027-2032 ($ millions)
Figure 72. Italy Targeted SSTR Radionuclide Drug Conjugates Market Size 2027-2032 ($ millions)
Figure 73. Russia Targeted SSTR Radionuclide Drug Conjugates Market Size 2027-2032 ($ millions)
Figure 74. Egypt Targeted SSTR Radionuclide Drug Conjugates Market Size 2027-2032 ($ millions)
Figure 75. South Africa Targeted SSTR Radionuclide Drug Conjugates Market Size 2027-2032 ($ millions)
Figure 76. Israel Targeted SSTR Radionuclide Drug Conjugates Market Size 2027-2032 ($ millions)
Figure 77. Turkey Targeted SSTR Radionuclide Drug Conjugates Market Size 2027-2032 ($ millions)
Figure 78. Global Targeted SSTR Radionuclide Drug Conjugates Market Size Market Share Forecast by Type (2027-2032)
Figure 79. Global Targeted SSTR Radionuclide Drug Conjugates Market Size Market Share Forecast by Application (2027-2032)
Figure 80. GCC Countries Targeted SSTR Radionuclide Drug Conjugates Market Size 2027-2032 ($ millions)
Figure 1. Targeted SSTR Radionuclide Drug Conjugates Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global Targeted SSTR Radionuclide Drug Conjugates Market Size Growth Rate (2021-2032) ($ millions)
Figure 6. Targeted SSTR Radionuclide Drug Conjugates Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 7. Targeted SSTR Radionuclide Drug Conjugates Sales Market Share by Country/Region (2025)
Figure 8. Targeted SSTR Radionuclide Drug Conjugates Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 9. Global Targeted SSTR Radionuclide Drug Conjugates Market Size Market Share by Type in 2025
Figure 10. Global Targeted SSTR Radionuclide Drug Conjugates Market Size Market Share by Radionuclide Type in 2025
Figure 11. Global Targeted SSTR Radionuclide Drug Conjugates Market Size Market Share by Targeting Vector Type in 2025
Figure 12. Targeted SSTR Radionuclide Drug Conjugates in Hospital
Figure 13. Global Targeted SSTR Radionuclide Drug Conjugates Market: Hospital (2021-2026) & ($ millions)
Figure 14. Targeted SSTR Radionuclide Drug Conjugates in Specialist Clinic
Figure 15. Global Targeted SSTR Radionuclide Drug Conjugates Market: Specialist Clinic (2021-2026) & ($ millions)
Figure 16. Targeted SSTR Radionuclide Drug Conjugates in Other
Figure 17. Global Targeted SSTR Radionuclide Drug Conjugates Market: Other (2021-2026) & ($ millions)
Figure 18. Global Targeted SSTR Radionuclide Drug Conjugates Market Size Market Share by Application in 2025
Figure 19. Global Targeted SSTR Radionuclide Drug Conjugates Revenue Market Share by Player in 2025
Figure 20. Global Targeted SSTR Radionuclide Drug Conjugates Market Size Market Share by Region (2021-2026)
Figure 21. Americas Targeted SSTR Radionuclide Drug Conjugates Market Size 2021-2026 ($ millions)
Figure 22. APAC Targeted SSTR Radionuclide Drug Conjugates Market Size 2021-2026 ($ millions)
Figure 23. Europe Targeted SSTR Radionuclide Drug Conjugates Market Size 2021-2026 ($ millions)
Figure 24. Middle East & Africa Targeted SSTR Radionuclide Drug Conjugates Market Size 2021-2026 ($ millions)
Figure 25. Americas Targeted SSTR Radionuclide Drug Conjugates Value Market Share by Country in 2025
Figure 26. United States Targeted SSTR Radionuclide Drug Conjugates Market Size Growth 2021-2026 ($ millions)
Figure 27. Canada Targeted SSTR Radionuclide Drug Conjugates Market Size Growth 2021-2026 ($ millions)
Figure 28. Mexico Targeted SSTR Radionuclide Drug Conjugates Market Size Growth 2021-2026 ($ millions)
Figure 29. Brazil Targeted SSTR Radionuclide Drug Conjugates Market Size Growth 2021-2026 ($ millions)
Figure 30. APAC Targeted SSTR Radionuclide Drug Conjugates Market Size Market Share by Region in 2025
Figure 31. APAC Targeted SSTR Radionuclide Drug Conjugates Market Size Market Share by Type (2021-2026)
Figure 32. APAC Targeted SSTR Radionuclide Drug Conjugates Market Size Market Share by Application (2021-2026)
Figure 33. China Targeted SSTR Radionuclide Drug Conjugates Market Size Growth 2021-2026 ($ millions)
Figure 34. Japan Targeted SSTR Radionuclide Drug Conjugates Market Size Growth 2021-2026 ($ millions)
Figure 35. South Korea Targeted SSTR Radionuclide Drug Conjugates Market Size Growth 2021-2026 ($ millions)
Figure 36. Southeast Asia Targeted SSTR Radionuclide Drug Conjugates Market Size Growth 2021-2026 ($ millions)
Figure 37. India Targeted SSTR Radionuclide Drug Conjugates Market Size Growth 2021-2026 ($ millions)
Figure 38. Australia Targeted SSTR Radionuclide Drug Conjugates Market Size Growth 2021-2026 ($ millions)
Figure 39. Europe Targeted SSTR Radionuclide Drug Conjugates Market Size Market Share by Country in 2025
Figure 40. Europe Targeted SSTR Radionuclide Drug Conjugates Market Size Market Share by Type (2021-2026)
Figure 41. Europe Targeted SSTR Radionuclide Drug Conjugates Market Size Market Share by Application (2021-2026)
Figure 42. Germany Targeted SSTR Radionuclide Drug Conjugates Market Size Growth 2021-2026 ($ millions)
Figure 43. France Targeted SSTR Radionuclide Drug Conjugates Market Size Growth 2021-2026 ($ millions)
Figure 44. UK Targeted SSTR Radionuclide Drug Conjugates Market Size Growth 2021-2026 ($ millions)
Figure 45. Italy Targeted SSTR Radionuclide Drug Conjugates Market Size Growth 2021-2026 ($ millions)
Figure 46. Russia Targeted SSTR Radionuclide Drug Conjugates Market Size Growth 2021-2026 ($ millions)
Figure 47. Middle East & Africa Targeted SSTR Radionuclide Drug Conjugates Market Size Market Share by Region (2021-2026)
Figure 48. Middle East & Africa Targeted SSTR Radionuclide Drug Conjugates Market Size Market Share by Type (2021-2026)
Figure 49. Middle East & Africa Targeted SSTR Radionuclide Drug Conjugates Market Size Market Share by Application (2021-2026)
Figure 50. Egypt Targeted SSTR Radionuclide Drug Conjugates Market Size Growth 2021-2026 ($ millions)
Figure 51. South Africa Targeted SSTR Radionuclide Drug Conjugates Market Size Growth 2021-2026 ($ millions)
Figure 52. Israel Targeted SSTR Radionuclide Drug Conjugates Market Size Growth 2021-2026 ($ millions)
Figure 53. Turkey Targeted SSTR Radionuclide Drug Conjugates Market Size Growth 2021-2026 ($ millions)
Figure 54. GCC Countries Targeted SSTR Radionuclide Drug Conjugates Market Size Growth 2021-2026 ($ millions)
Figure 55. Americas Targeted SSTR Radionuclide Drug Conjugates Market Size 2027-2032 ($ millions)
Figure 56. APAC Targeted SSTR Radionuclide Drug Conjugates Market Size 2027-2032 ($ millions)
Figure 57. Europe Targeted SSTR Radionuclide Drug Conjugates Market Size 2027-2032 ($ millions)
Figure 58. Middle East & Africa Targeted SSTR Radionuclide Drug Conjugates Market Size 2027-2032 ($ millions)
Figure 59. United States Targeted SSTR Radionuclide Drug Conjugates Market Size 2027-2032 ($ millions)
Figure 60. Canada Targeted SSTR Radionuclide Drug Conjugates Market Size 2027-2032 ($ millions)
Figure 61. Mexico Targeted SSTR Radionuclide Drug Conjugates Market Size 2027-2032 ($ millions)
Figure 62. Brazil Targeted SSTR Radionuclide Drug Conjugates Market Size 2027-2032 ($ millions)
Figure 63. China Targeted SSTR Radionuclide Drug Conjugates Market Size 2027-2032 ($ millions)
Figure 64. Japan Targeted SSTR Radionuclide Drug Conjugates Market Size 2027-2032 ($ millions)
Figure 65. Korea Targeted SSTR Radionuclide Drug Conjugates Market Size 2027-2032 ($ millions)
Figure 66. Southeast Asia Targeted SSTR Radionuclide Drug Conjugates Market Size 2027-2032 ($ millions)
Figure 67. India Targeted SSTR Radionuclide Drug Conjugates Market Size 2027-2032 ($ millions)
Figure 68. Australia Targeted SSTR Radionuclide Drug Conjugates Market Size 2027-2032 ($ millions)
Figure 69. Germany Targeted SSTR Radionuclide Drug Conjugates Market Size 2027-2032 ($ millions)
Figure 70. France Targeted SSTR Radionuclide Drug Conjugates Market Size 2027-2032 ($ millions)
Figure 71. UK Targeted SSTR Radionuclide Drug Conjugates Market Size 2027-2032 ($ millions)
Figure 72. Italy Targeted SSTR Radionuclide Drug Conjugates Market Size 2027-2032 ($ millions)
Figure 73. Russia Targeted SSTR Radionuclide Drug Conjugates Market Size 2027-2032 ($ millions)
Figure 74. Egypt Targeted SSTR Radionuclide Drug Conjugates Market Size 2027-2032 ($ millions)
Figure 75. South Africa Targeted SSTR Radionuclide Drug Conjugates Market Size 2027-2032 ($ millions)
Figure 76. Israel Targeted SSTR Radionuclide Drug Conjugates Market Size 2027-2032 ($ millions)
Figure 77. Turkey Targeted SSTR Radionuclide Drug Conjugates Market Size 2027-2032 ($ millions)
Figure 78. Global Targeted SSTR Radionuclide Drug Conjugates Market Size Market Share Forecast by Type (2027-2032)
Figure 79. Global Targeted SSTR Radionuclide Drug Conjugates Market Size Market Share Forecast by Application (2027-2032)
Figure 80. GCC Countries Targeted SSTR Radionuclide Drug Conjugates Market Size 2027-2032 ($ millions)
